Medication info
Emplom Extended-release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

Emplom Extended-release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White and light blue, oval, double convex extended-release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500550 · Approved 2025.03.12 · Insurance code 645907590

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening. Take one 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. Older adults In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
View approved original text

This medication is used to help control blood sugar in adults with Type 2 diabetes who are following dietary and exercise regimens. In particular, it effectively manages blood sugar levels by using a combination of empagliflozin and metformin in patients whose blood sugar control is inadequate. Additionally, it may help reduce the risk of cardiovascular events in adults with Type 2 diabetes and cardiovascular disease. It is important to refer to expert guidelines and precautions during use to ensure safe administration. This medication assists in managing blood sugar levels and cardiovascular health.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening. Take one 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse reactions and 6. Interactions). Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. Older adults In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This medication helps lower blood sugar levels. However, it may rarely cause a serious condition called lactic acidosis, so caution is needed. Additionally, when used with insulin or other diabetes medications, hypoglycemia may occur, requiring careful monitoring. This drug should not be used in patients with impaired renal function, acute kidney issues, severe infections, heart failure, or acute myocardial infarction. In particular, if renal function is moderately reduced or worse, use should be prohibited, and regular kidney function tests should be performed. This drug should be temporarily stopped before and after surgery or tests involving radiocontrast agents. It should not be used in pregnant women or those with placental dysfunction, patients with liver impairment, or those with severe lung diseases. As this medication contains lactose, individuals with lactose intolerance should avoid it. During treatment, it is important to be vigilant for symptoms of hypoglycemia and signs of infection, as the risk of urinary and genital infections may be increased. Those with fluid depletion, dehydration, or cardiovascular disease should be monitored closely. There may be a decrease in vitamin B12 levels, so regular testing is advisable if necessary. Avoiding alcohol is important, as it may increase the risk of lactic acidosis. Furthermore, the tablets should be swallowed whole without chewing or crushing, and it is acceptable if the tablet coating is expelled unchanged. Elderly patients may have a higher risk of renal function decline, requiring dosage adjustment and regular monitoring of kidney function. In cases of overdose, especially with a risk of lactic acidosis, prompt medical attention is necessary, and blood dialysis may be needed to remove the drug. Finally, during the course of this medication, do not combine it with other medications without consulting a doctor, and report any unusual symptoms to a healthcare professional immediately.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • decreased fluid volume
  • nausea
Show 166 more
  • vomiting
  • diarrhea
  • abdominal pain
  • decreased appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • increased urination
  • urinary difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • decreased and deficient vitamin B12
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue inflammation
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • intestinal bleeding
  • headache
  • dizziness
  • cerebral infarction
  • postural dizziness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vulvovaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • hypersomnia
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • contact dermatitis
  • prickly heat
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurry vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein obstruction
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exercise-induced dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • bruise
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disorders
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • postural dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture and should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness and safety for a long time.

Appearance and packaging

Appearance

White and light blue, oval, double convex extended-release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.